Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2006, Pages

  Nabi, Ghulam ^a   Cody, June D ^a   Ellis, Gaye ^b   Hay Smith, Jean ^c   Herbison, G Peter ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; OVERACTIVE BLADDER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYNDROME;

ADULT; CHOLINERGIC ANTAGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SYNDROME; URINARY BLADDER, OVERACTIVE;

EID: 34247208991     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003781.pub2     Document Type: Review

References (176)

1. Abrams P, Jackson S, Mattiasson A, Krishnan K, Haendler L. A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia. Proceedings of the International Continence Society 26th Annual Meeting. 1996:276-7.
2. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. British Journal of Urology 1998;81:801-10.
3. Abrams P, Freeman RN, Anderstrom C, Mattiasson A. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability. Journal of Urology Annual Meeting. 1997; Vol. 157(4):103.
4. Abrams P, Kaplan S, Millard R. Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Proceedings of the International Continence Society, 32nd Annual Meeting,Seoul. 2001.
5. Alloussi S, Laval K U, Ballering-Bruhl B, Grobe-Freese M, Bulitta M, Schafer M. Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study. Journal of Clinical Research 1998;1:439-51.
6. Bagger P, Fischer-Rasmussen W, Hansen RI. Emepronium carregeenate: clinical effects and urinary excretion in treatment of female urge incontinence. Scandanavian Journal of Urology and Nephrology 1985;19:31-5. [MEDLINE: 85272439]
7. Bagger PV, Fischer-Rasmussen W. [Emepronium carragenate in the treatment of female urinary motor-urge incontinence]. Proceedings of the 14th Annual Meeting of the International Continence Society; 1984 Sep 13-15; Innsbruck. 1984:304.
8. Bono AV, Marconi AM, Gianneo E. Oxybutynin for Unstable Bladder. A preliminary placebo controlled trial [L'ossibutinina cloridrato nella vescica instabile pura (Italian)]. Urologia 1982;49:764-8.
9. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. Journal of the American Geriatrics Society 2000;48:370-4.
10. Burgio KL, Locher JL, Goode PS, Hardin M, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA 1998;280(23):1995-2000.
11. Burgio KL, Locher JL, Roth DL, Goode PS. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. Journal of Gerontology: Psychological Sciences 2001;56B(1):46-51.
12. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicentre clinical trial. British Journal of Urology International 2000;85:659-64.
13. Cardozo L, Lisec M, Millard R, van Vierssen Trip O, Kuzmin I, Drogendijk TE, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Journal of Urology 2004;172(5(Pt 1 of 2)):1919-24. [MEDLINE: 19090]
14. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International 2005;95(1):81-5. [MEDLINE: 20241]
15. Chaliha C, Halaska M, Stanton S. Trospium chloride for the treatment of detrusor instability: a placebo-controlled dose-finding study. British Journal of Obstetrics and Gynaecology 1998;105(Suppl 17):276.
16. Chapple CR, Arano P, Bosch JHR, De Ridder D, Kramer G, Ridder AM. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract). Neurourology and Urodynamics 2002;21(4):381-2. [MEDLINE: 14551]
17. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU International 2004;93(1):71-7. [MEDLINE: 17334]
18. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU International 2005;95(1):81-5. [MEDLINE: 20241]
19. Chapple CR, Rechberger T, Al Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU International 2004;93(3):303-10. [MEDLINE: 17270]
20. Coombes GM, Millard RJ. A randomised double blind placebo controlled trial of penthienate in the treatment of detrusor instability (Abstract). Proceedings of the International Continence Society 24th Annual Meeting; 1994 Aug 30 - Sept 2; Prague, Czech Republic; 1994 104. [MEDLINE: 17191]
21. Coombes GM, Millard RJ. Urinary urge incontinence: randomised crossover trials of penthienate versus placebo and propantheline. Medical Journal of Australia 1996;165(9):473-6. [MEDLINE: 4862]
22. Davila GW, Sanders S, for the Transdermal Oxybutynin Study Group. Transdermal oxybutynin: A multi-center, prospective, randomized, double-blind, placebo-controlled study in adults with urge urinary incontinence. International Urogynecology Journal 2001;12(Suppl 3):S43.
23. Davila GW, Sanders SW, Lyttle S, Gittelman MC, Zinner N, Saltzstein DR et al for the Transdermal Oxybutynin Study Group. Transdermal oxybutynin is safe, effective, and improves quality of life in patients with overactive bladder. Neurourology and Urodynamics 2001;20(4):426-7.
24. Di Stasi SM, Giannantoni A, Vespasiani G, Navarra P, Capelli G, Massoud R, et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. Journal of Urology 2001;165:491-8. [MEDLINE: 11176403]
25. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62(2):237-42. [MEDLINE: 16528]
26. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Murtz G, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. European Urology 2000;37:702-8.
27. Drutz H, Appell RA. Clinical efficacy and safety of Tolterodine vs Oxybutynin and placebo in patients with unstable bladder. Acta Obstetrica et Gynecologica Scandinavica 1997;Suppl 167(5):24.
28. Drutz HP, Appell RA. Enhanced tolerability of Tolterodine compared to Oxybutynin in a controlled clinical study. International Urogynecology Journal and Pelvic Floor Dysfunction 1997;8(1):S14.
29. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International Urogynecology Journal 1999;10:283-9.
30. Freeman R, Hill S, Millard R, Slack M, Sutherst J, Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstetrics and Gynecology 2003;102(3):605-11. [MEDLINE: 16494]
31. Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. Journal of the American Geriatrics Society 2002;50(5):808-16. [MEDLINE: 14678]
32. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. European Urology 2004;45(4):420-9. [MEDLINE: 17428]
33. Halaska M, Dorschner W, Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourology and Urodynamics 1994;13(4):428-30.
34. Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World Journal of Urology 2004;22(4):251-6. [MEDLINE: 19412]
35. Homma Y, Paick JS, Lee JG, Kawabe K, Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International 2003;92(7):741-7. [MEDLINE: 16418]
36. Jacquetin B, Wyndaele JJ. Tolterodine reduces the number of incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics and Gynecology and Reproductive Biology 2001;98:97-102.
37. Jacquetin B, Wyndaele JJ. Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity. International Urogynecology Journal and Pelvic Floor Dysfunction 1997;8(1):S30.
38. Jonas U, Hofner K, Madersbacher H. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World Journal of Urology 1997;15:144-51.
39. Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of Tolterodine compared to placebo in patients with detrusor overactivity. Neurourology and Urodynamics 1997;16(5):477-8.
40. Junemann KP, Fusgen I. Placebo-controlled, randomised, double-blind, multicentre clinical trial on the efficacy and tolerability of 1 x 40 mg and 2 x 40 mg trospium chloride (Spasmo-lyt) daily for 3 weeks in patients with urge-syndrome. Neurourology and Urodynamics 1999;18(4):375-6.
41. Junemann KP, Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double-blind, placebo-controlled, multicentre clinical trial. Neurourology and Urodynamics 2000;19(4):488-90.
42. Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004;64(2):269-74; discussion 274-5. [MEDLINE: 19498]
43. Kramer AEJL, Zeegers AGM, Kiesswetter H, Jonas U. Drug treatment of urgency: a double blind trial of cetiprin®, dridase®, urispas® and placebo [Medicamenteuze behandeling van overmatige mictiedrang: Dubbel-blind onderzoek van cetiprin®, dridase®, urispas® en placebo (Flemish)]. TGO tijdschrift voor Therapie, Geneesmiddel, en Onderzoek 1987;12(7):256-61.
44. Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. Journal of Urology 2004;171(2 (Pt 1)):752-6. [MEDLINE: 17327]
45. Halaska M, Madersbacher H, Voigt R, Hofner K, Martan A. Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicenter study comparing its tolerability and efficacy with oxybutynin. International Urogynaecology Journal and Pelvic Floor Dysfunction 2000;11(Suppl 1):46.
46. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. British Journal of Urology International 1999;84:646-51.
47. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A urodynamically controlled multicenter study in patients with urge incontinence: tolerability and efficacy of propiverine hydrochloride in comparison to oxybutynin. Proceedings of the International Continence Society 27th Annual Meeting. 1997:153-4.
48. Malone-Lee JG, Walsh B, Maugourd MF and the Tolterodine in the Elderly Study Group. The safety and clinical efficacy of two doses of Tolerodine, compared to placebo in elderly patients. Proceedings of the International Continence Society. 1997:155-6.
49. Malone-Lee JG, Walsh JB, Maugourd M-F, and the Tolterodine in the Elderly Study Group. Tolterodine: A safe and effective treatment for older patients with overactive bladder. Journal of the American Geriatric Society 2001;49:700-5.
50. Massey JA, Abrams P. Dose titration in clinical trials. An example using emepronium carrageenate in detrusor instability. British Journal of Urology 1986;58:125-8.
51. Massey JA, Abrams PH. Dose-titrated emepronium carrageenate for detrusor instability. Proceedings of the International Continence Society 14th Annual Meeting. 1984:109-10.
52. Meyhoff H H, Gerstenberg TC, Nordling J. Placebo - the drug of choice in female motor urge incontinence?. British Journal of Urology 1983;55:34-7.
53. Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis B. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. Journal of Urology 1999;161:1551-5.
54. Moore K, Millard R, Dwyer P, Tuttle J. A randomized controlled multicentre trial of Tolterodine in detrusor instability/hyperreflexia. International Urogynecology Journal and Pelvic Floor Dysfunction 1997;8(1):S129.
55. Rosamilia A, Dwyer PL, Clarke B, Moore K, Millard RP, Tuttle J. The clinical efficacy and safety of two doses of Tolterodine in detrusor instability. Acta Obstetrica et Gynecologica Scandinavica 1997;167(5):24.
56. Bary PR, Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Progress in Clinical & Biological Research 1981;78:313-9.
57. Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. British Journal of Urology 1980;52:472-5.
58. Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride (3mg) in the treatment of women with idiopathic detrusor instabilty. British Journal of Urology 1990;66:479-85.
59. Moore KH, Hay DM, Imrie AH, Cockin J. Randomized double blind placebo-controlled trial of oxybutynin in females with detrusor instability. Proceedings of the Annual Meeting of the International Continence Society. 1987:137-8.
60. Moore KH, Sutherst JR. Response to treatment of detrusor instability in relation to psychoneurotic status. British Journal of Urology 1990;66:486-90.
61. Murray KHA, Patterson JR, Stephenson TP. A double-blind three way cross over placebo controlled trial of cystrin and cetiprin novum. Proceedings of the 14th annual Meeting of the International Continence Society. 1984:454.
62. Rentzhog SL, Stanton L, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. British Journal of Urology 1998;81:42-8.
63. Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clinical and Experimental Obstetrics and Gynecology 1984;XI(1-2):37-42.
64. Rosario DJ, Leaker BR, Noble JG, Milroy E, Chapple CR. A double-blind placebo controlled crossover study of the effects of single doses of darifenacin on cystometric parameters in patients with detrusor instability. Proceedings of the 25th Annual Meeting of the International Continence Society. 1995:223.
65. Rosario DJ, Leaker BR, Smith DJ, Chapple CR. A pilot study of the effects of multiple doses of the M3 muscarinic receptor agonist darifenacin on ambulatory parameters of detrusor activity in patients with detrusor instability (Abstract 36). Neurourology and Urodynamics 1995;14(5):464-5.
66. Serrano Brambila EA, Avila RGQ, Monterrubio JLL, Aranda JM. Evaluation of the effectiveness and tolerance of oxybutynin in the treatment of unstable bladder [Evaluación de la efectividad y tolerancia de la oxibutinina en la tratamiento de la vejiga inestable en la mujer (Spanish)]. Ginecologia y Obstetricia de México 2000;68:174-81.
67. Stohrer M, Bauer P, Giannetti BM, Richter R, Burgdorfer H, Murtz G. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urologia Internationalis 1991;47:138-43.
68. Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - A double-blind, placebo-controlled clnical trial. Spinal Cord 1999;37:196-200.
69. Collas DM, Szonyi G, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in the elderly - a placebo controlled trial. Age and Ageing 1994;23(Suppl. 2):9.
70. Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: A randomised controlled trial. Age and Ageing 1995;24:287-91.
71. Tago K, Ueno A, Takayasu H. Clinical study of propiverine hydrochloride for the treatment of patients with urinary frequency and incontinence. Neurourology and Urodynamics 1990;9(4):337-8.
72. Takayasu H, Ueno A, Tsutida S, Koiso K, Kurita K, Kawabe K, et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine) 1990;153:459-71. [MEDLINE: 12896]
73. Cardozo LD, Cooper D, Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability (Abstract 88). Neurourology and Urodynamics 1987;6(3):256-7.
74. Tapp AJS, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. British Journal of Obstetrics and Gynaecology 1990;97(June):521-6.
75. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin vs. propantheline vs. placebo. Neurourology and Urodynamics 1990;9(4):337-8.
76. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology 1991;145(April):813-7.
77. Ulshofer B, Bihr AM, Bodeker RH, Schwantes U, Jahn HP. Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clinical Drug Investigation 2001;21(8):563-9.
78. Ulshofer B, Schwantes U, Bodeker RH, Bihr AM, Jahn HP. Efficacy and tolerance of trospium chloride in patients with motor urge incontinence - results of a randomised double-blind placebo-controlled study. Proceedings of the International Consultation on Incontinence (ICI), Paris. 2001:5.
79. Messelink EJ, Soler JM, Madersbacher H, Thuroff JW, Amarenco G, van Kerrebroeck PEV. Urodynamic aspects of the efficacy of tolterodine, a new anti muscarine drug in the treatment of detrusor hyperreflexia. Proceedings of the International Continence Society 25th Annual Meeting. 1995:95-6.
80. Van Kerrebroeck PEVA, Amarenco G, Thuroff JW, Madersbacher HG, Lock MTWT, Messelink EJ, Soler JM. Dose-ranging study ot tolterodine in patients with detrusor hyperreflexia. Neurourology and Urodynamics 1998;17:499-512.
81. Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clinical Drug Investigation 2000 Feb;19(2):83-91.
82. Garely A, on behalf of the Tolterodine Study Group. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder. International Urology Journal 2001;12(Suppl):18.
83. Kelleher CJ, Pleil AM, Okano GJ, Reese PR. Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourology and Urodynamics 2001;20(4):504-6.
84. Kelleher CJ, Pleil AM, Okano GJ, Reese PR. Long-term health-related quality of patients with overactive bladder receiving Tolterodine. Proceedings of the International Continence Society Annual Meeting, Seoul. 2001:No. 82.
85. Kelleher CJ, Pleil AM, Reese PR. Health related quality of life of patients with overactive bladder receiving tolterodine once-daily. Neurourology and Urodynamics 2000;19(4):519-21.
86. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care 2002;8 Suppl 19:608-15. [MEDLINE: 17998]
87. Kelleher CJ, on behalf of the Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal 2000;11(Suppl 1):94.
88. Kreder KJ. Antimuscarinic therapy: relationship between efficacy and side effects in responders and non-responders. Journal of Urology 2001;165, May(5 Suppl):S165.
89. Kreder KJ. Clinical effectiveness of antimuscarinic therapy: the relationship between efficacy and tolerability. Proceedings of the International Continence Society Annual Meeting, Seoul. 2001:No. 140.
90. Mallett V, on behalf of the Tolterodine Study Group. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder. International Urogynecology Journal 2001;12(Suppl 1):4.
91. Swift S. Efficacy and tolerability of once-daily Tolterodine for women with overactive bladder. Proceedings of the International Continence Society Annual Meeting, Seoul. 2001:No. 329.
92. Swift S. Once-daily tolterodine is effective and well tolerated in women with overactive bladder. 2nd International Consultation on Incontinence, Paris. July 2001:Abstract 57.
93. Swift SE. Once-daily (OD) tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder (OAB). International Urogynecology Journal 2000;11(Suppl. 1):15.
94. Swift SE. Once-daily administration of extended-release tolterodine is effective and well-tolerated in patients with oveactive bladder. Proceedings of the XVI FIGO World Congress of Obstetrics & Gynecology; 3-8 Sept; Washington DC. 2000; Vol. Book 1:40.
95. Swift SE. Overactive bladder in females: treatment with once-daily Tolterodine. International Urogynecology Journal 2001;12(Suppl 3):71.
96. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001;57:414-21.
97. Van Kerrebroeck PEV. Long-term (12 months) efficacy and tolerability of tolterodine once-daily in the treatment of overactive bladder. Neurourology and Urodynamics 2001;20(4):401-2.
98. Van Kerrebroeck PEVA, for the Tolterodine Study Group. Long-term tolerability and efficacy of once-daily (OD) Tolterodine in the treatment of overactive bladder (OB). International Urogynecology Journal 2001;12(Suppl 3):49.
99. Van Kerrebroeck PEVA, on behalf of the Tolterodine Study Group. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder. Neurourology and Urodynamics 2000;19(4):493-4.
100. Walter S, Hansen J, Hansen L, Maegaard E, Meyhoff HH, Nordling J. Urinary incontinence in old age. A controlled clinical trial of Emepronium Bromide. British Journal of Urology 1982;54:249-51.
101. Wehnert VJ, Sage S. Comparative study of the effect of Mictonorm (Propiverine hydrochloride) and Spasuret (Flavoxate hydrochloride) on the bladder detrusor muscle [Vergleichende untersuchungen zur wirkung von Mictonorm (Propiverin hydrodhlorid) und Spasuret (Flavoxat hydrochlorid) auf den detrusor vesicae (German)]. Zentralblatt für Urologie und Nephrologie 1989;82:259-63.
102. Wehnert VJ, Sage S. Treatment of bladder unstability and urge incontinence with Propiverine Hydrochloride (Mictonorm®) and Oxybutynin chloride (Dridase®) - a randomised crossover study [Therapie der blaseninstabilität und urge-inkontinenz mit Propiverin hydrochlorid (Mictonorm®) und Oxybutinin chlorid (Dridase®) - eine randomisierte cross-over-vergleichsstudie (German)]. Aktuelle Urologie 1992;23:7-11.
103. Wein AJ, Hanno PM, Raezer DM, Benson GS. Effect of oxybutynin chloride on bladder spasm following transurethral surgery. Urology 1978;XII(2):184-6.
104. Zeegers AGM, Kiesswetter H, Kramer AEJL, Jonas U. Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo. World Journal of Urology 1987;5:57-61.
105. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. Journal of the American Geriatrics Society 2002;50(5):799-807. [MEDLINE: 14679]
106. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. Journal of Urology 2004;171(6 (Pt 1)):2311-5. [MEDLINE: 17376]
107. Zorzitto ML, Holliday PJ, Jewett MAS, Herschorn S, Fernie GR. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age and Ageing 1989;18:195-200.
108. Alloussi S, Laval K-U, Mertins B. Efficacy and tolerability of trospium chloride (spasmo-lyt) versus placebo in patients with motor urge-syndrome. Proceedings of the International Continence Society (ICS), 28th Annual Meeting; 1998 Sept 14-17; Jerusalem, Israel; 1998 109-10. [MEDLINE: 5684]
109. Andersen JR, Lose G, Norgaard M, Stimpel H, Andersen JT. Terodiline, Emepronium bromide or placebo for treatment of female detrusor overactivity? A randomized, double-blind cross-over study. Proceedings of the International Continence Society (ICS), 17th Annual Meeting; 1987 Sept 2-5; Bristol,UK; 1987 1-2. [MEDLINE: 9025]
110. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997;50(Suppl 6A):90-6.
111. Baert L, Leuven G, Dijkman B, the Darifenacin study group. [Darifenacin, a novel M3 muscarinic receptor antagonist in detrusor overactivity [Read by title abstract]]. Proceedings of the 25th Annual Meeting of the International Continence Society, Sydney, Australia. 1995.
112. Brocklehurst JC, Armitage P, Jouher AJ. Emepronium bromide in urinary incontinence. Age and Ageing 1972;1:152-7.
113. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Candib D. Behavior vs drug therapy for urge incontinence in older women (Abstract). Proceedings of the American Urogynecology Society, 15th Annual Scientific Meeting; 1994 Sept 21-24; Toronto, Ontario. 1994:48 (Abstract 26).
114. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. Journal of Urology 2005;173(4):1214-8. [MEDLINE: 20180]
115. Chapple CR, Madersbacher H, Dreikorn K, Dorschner W, Murtz G. Urodynamics and frequency/volume chart - do they correlate? Treatment analysis of Propiverine in comparison to Oxybutynin and Placebo in urge incontinence (Abstract). Proceedings of the International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21; Seoul, Korea. 2001:Abstract 224. [MEDLINE: 14474]
116. Chapple CR, Arano P, Bosch JHR, De Ridder D, Kramer G, Ridder AM. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study (Abstract). Neurourology and Urodynamics 2002;21(4):381-2. [MEDLINE: 14551]
117. Chapple C, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Ridder A. Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with symptomatic overactive bladder (Abstract). Neurourology and Urodynamics 2003;22(5):534-5. [MEDLINE: 16991]
118. Chapple C. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study (Abstract). Neurourology and Urodynamics 2004;23(5/6):598-9. [MEDLINE: 19023]
119. Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. British Journal of Urology International 2005;95(7):993-1001. [MEDLINE: 20340]
120. Coombes GM, Millard RJ. A randomised double blind placebo controlled trial of penthienate in the treatment of detrusor instability (Abstract). Proceedings of the International Continence Society 24th Annual Meeting; 1994 Aug 30 - Sept 2; Prague, Czech Republic; 1994 104. [MEDLINE: 17191]
121. Davila GW, Daugherty CA, Sanders SW, for The Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. Journal of Urology 2001;166(July):140-5.
122. Di Stasi SV, Giannantoni A, Navarra P, Capelli G, Storti L, Porena M, Stephen RL. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and n-desethyl oxybutynin. Journal of Urology 2001;166:2232-6.
123. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Brunjes R, Frank M, et al. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine]. [German]. Aktuelle Urologie 2003;34(2):102-8. [MEDLINE: 16422]
124. Gerstenberg TC, Klarskov P, Ramirez D, Hald T. Terodiline in the treatment of women with urgency and motor urge incontinence. A clinical and urodynamic double-blind cross-over study. British Journal of Urology 1986;58(2):129-33. [MEDLINE: 574]
125. Goode PS. Behavioral and drug therapy for urinary incontinence. Urology 2004;63(Suppl 3A):58-64. [MEDLINE: 17295]
126. Griebenow R, Wieners F, Lange Th. Possible induction of cardiac dysrhythmia in elderly patients under therapy with propiverine hydrochloride. Neurourology and Urodynamics. 1994; Vol. 13:430-2.
127. Kirschner-Hermanns R, DuBeau C, Resnick NM. Oxybutynin for incontinence in institutionalized elderly - a re-evaluation. Proceedings of the International Continence Society 27th Annual Meeting. 1997:149-50.
128. Kuipers M, Tran DD, Krauwinkel W, Abila B, Mulder H. Absolute bioavailability of YM905 in healthy male volunteers: A single-dose, randomized, two-period crossover study (Abstract). Proceedings of the International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:296-7. [MEDLINE: 14531]
129. Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999;53(5):990-8.
130. Norton P, Karram M, Wall LL, Rosenzweig B, Benson JT, Fantl JA. Randomized double-blind trial of terodiline in the treatment of urge incontinence in women. Obstetrics & Gynecology 1994;84(3):386-91. [MEDLINE: 3]
131. Ouslander JG, Schelle JF, Uman G, Fingold S, Nigam JG, Tuico E. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents?. Journal of the American Geriatric Society 1995;43:610-7.
132. Robinson JM, Brocklehurst JC. Emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence associated with detrusor instability in elderly women. British Journal of Urology 1983;55:371-6.
133. Rosario DJ, Smith DJ, Radley SC, Chapple CR. Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: a study of methodology. Neurourology and Urodynamics 1999;18:223-34.
134. Rudy D, Cline K, Goldberg K, Harris R. A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients (Abstract). Neurourology & Urodynamics 2004;23(5/6):600-1. [MEDLINE: 19025]
135. Smith N, Grimes I, Ridge S, Tempel D, Uchida T, Yamanouchi USA. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study (Abstract). Proceedings of the International Continence Society (ICS), 32nd Annual Meeting; 2002 Aug 28-30; Heidelberg, Germany. 2002:138-9. [MEDLINE: 14508]
136. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Current Urology Reports 2004;5(6):423-6. [MEDLINE: 19422]
137. Takayasu H, Ueno A, Tsutida S, Koiso K, Kurita K, Kawabe K, et al. Clinical effects of propiverine hydrochloride in the treatment of urinary frequency and incontinence associated with detrusor overactivity: a double blind, parallel, placebo controlled multicenter study. Igaku No Ayumi (Progress in Medicine) 1990;153:459-71. [MEDLINE: 12896]
138. Tapp A, Fall M, Norgaard J, Massey A, Choa R, Carr T, et al. A dose-titrated, multicentre study of terodiline in the treatment of detrusor instability. Neurourololgy and Urodynamics. 6 1987; Vol. 6, issue 3:254-5. [MEDLINE: 3255]
139. Tapp A, Fall M, Norgaard J, Massey A, Choa R, Carr T, Korhonen M, Abrams P. Terodiline: a dose titrated, multicenter study of the treatment of idiopathic detrusor instability in women. Journal of Urology 1989;142(4):1027-31. [MEDLINE: 399]
140. Terodiline in the Elderly American Multicenter Study Group. Effects of terodiline on urinary incontinence among older non- institutionalized women. Journal of the American Geriatrics Society 1993;41(9):915-22. [MEDLINE: 88]
141. Viayna C, Alvarez D, Lopez R, Sanagustin J, Lagunas C. A randomised, placebo-controlled, dose-rising study in healthy males volunteers to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of SVT-40776, a novel selective M3 antimuscarinic (Abstract). Proceedings of the International Continence Society (34th Annual Meeting) and the International UroGynecological Association; 2004 Aug 23-27;Paris;. 2004:Abstract number 270. [MEDLINE: 19042]
142. Wagg A, Malone-Lee J. Pressure-flow variables in patients treated with tolterodine for detrusor overactivity. BJU International 2003;92(9):969-71. [MEDLINE: 16659]
143. Wein AJ, Appell RA. A comparison of the efficacy response profile of tolterodine and oxybutynin. International Urogynaecology Journal. 1999; Vol. 10 (Suppl 1):150.
144. Wein AJ, Appell RA. A comparison of the efficacy response profile of tolterodine and oxybutynin [Read by title abstract]. Proceedings of the 29th Annual Meeting of the International Continence Society; 1999 Aug 23-26; Denver, Colorado. 1999:252-3.
145. Whitehead JA. Urinary incontinence in the aged. Propantheline bromide as an adjunct to treatment. Geriatrics 1967;22(1):154-8.
146. Whitehead JA. Urinary incontinence in the aged. Propantheline bromide as an adjunct to treatment. Geriatrics 1967;22(1):154-8.
147. Williams AJ, Prematalake JKTG, Palmer RL. A trial of emepronium bromide for the treatment of urinary incontinence in the elderly mentally ill. Pharmatherapeutica 1981;2(8):539-42.
148. Abrams PH, Blaivas JG, Stanton SL, Andersen JT. Standardisation of terminology of lower urinary tract function. Neurourology and Urodynamics 1988;7(5):403-27.
149. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourology and Urodynamics 2002;21(2):167-78.
150. Alhasso AA, McKinley J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2006, Issue 4. [Art. No.: CD003193. DOI: 10.1002/14651858.CD003193.pub3]
151. Brieger GM, Yip SK, Hin LY, Chung TK. The prevalence of urinary dysfunction in Hong Kong Chinese women. Obstetrics and Gynecology 1996;88(6):1041-4.
152. Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstetrics and Gynecology 1999;94(1):66-70.
153. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. European Urology 2005;48(1):5-26.
154. Choo M-S, Lee YS, Kim HY, Lee JB, Kwon DD, Lee T, et al. The prevalence of overactive bladder in Korea. Proceedings of the International Continence Society. Seoul, 2001.
155. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50(Suppl 6A):36-52. [MEDLINE: 98088155]
156. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [update May 2005]; Section 8. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd, 2005.
157. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Brunjes R, Frank M, et al. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine]. [German]. Aktuelle Urologie 2003;34(2):102-8. [MEDLINE: 16422]
158. DuBeau CE, Miller KL, Bergmann M, Resnick NM. Urge incontinence outcomes in RCTs depend on assumed and not actual drug assignment [Abstract]. Neurourology and Urodynamics 2000;19(4):492.
159. Dublin N, Alhasso AA, Stewart L. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 2004, Issue 2. [Art. No.: CD003190. DOI: 10.1002/14651858.CD003190.pub2]
160. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults?. Cochrane Database of Systematic Reviews 2005, Issue 3. [Art. No.: CD005429. DOI: 10.1002/14651858.CD005429]
161. Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. Journal of Neurology 1999;246(11):1027-32.
162. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd, 2005.
163. Jackson S. The patient with an overactive bladder - symptoms and quality of life issues. Urology 1997;50(Suppl. 6A):18-22.
164. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50(6A suppl):100-7. [MEDLINE: 98088168]
165. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20(4):470-5.
166. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU International 2001;87(9):760-6.
167. Moller LA, Lose G, Jorgensen T. The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstetrica et Gynecologica Scandinavica 2000;79(4):298-305.
168. Moothy P, Lapitan MC, Lim PHC. Prevalence of overactive bladder in Asian males: an epidemiologic survey. Proceedings of the International Continence Society. Seoul, 2001.
169. Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. JAMA 1982;248(10):1194-8. [MEDLINE: 82269350]
170. Ouslander JG, Hepps K, Raz S, Su HL. Genitourinary dysfunction in a geriatric outpatient population. Journal of the American Geriatric Society 1986;34(7):507-14. [MEDLINE: 86251890]
171. Pleil AM, Coyne KS, Reese PR, Jumadilova Z. The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue-The BSW. Value in Health 2005;8:S25-34.
172. Roland M, Torgerson DJ. What are pragmatic trials?. BMJ 1998;316:285.
173. Stewart WF, Corey R, Herzog AR, Wein A, Norton PA, Payne C, et al. Prevalence of overactive bladder in women: results from the Noble Program. International Urogynecology Journal. 2001; Vol. 12 (3):66.
174. Ueda T, Tamaki M, Kageyama S, Yoshimura N, Yoshida O. Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. International Journal of Urology 2000;7(3):95-103.
175. van Kerrebroeck PHEV, for the Tolterodine study group. Long-term tolerability and efficacy of once-daily (OD) tolterodine in the treatment of overactive bladder (OAB). International Urogynecology Journal. 2001; Vol. 12 (Suppl 3):549.
176. Wallace S, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database of Systematic Reviews 2004, Issue 1. [Art. No.: CD001308. DOI: 10.1002/14651858.CD001308.pub2]